Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis.

From Hollywood A-listers to everyday people using Ozempic (semaglutide) for weight loss, the side effect has left many ...

Researchers conducted a post hoc analysis of the PIONEER trials to compare the efficacy of oral semaglutide versus active comparators in improving T2D cardiometabolic outcomes.

For patients with symptomatic peripheral artery disease and type 2 diabetes, semaglutide use is associated with increased walking distance.

The General Directorate of Drugs, Food, and Health Products (Digemaps) issued a public warning about unapproved weight-loss ...

Neoadjuvant semaglutide showed no benefit in weight loss, diabetes remission or safety in a cohort of patients who underwent ...

Real Housewives of New Jersey” star Jennifer Fessler didn’t follow her doctor’s advice when she started taking a GLP-1 weight ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

The cohort study used data from the TriNetX database, encompassing patients diagnosed with diabetes and prescribed ...